In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Enanta Pharmaceuticals (ENTA), with a price target of $100. The company’s shares closed yesterday at $83.80.
Olson commented:
“ENTA reported 1QFY19 financial results, including $69.9M HCV royalties (just short of $71.3M consensus) and $1.25 EPS (below the $1.35 consensus). ENTA described progress with several pipeline candidates that should result in catalysts this year, including: 1) preclinical data for EDP-514 in HBV and ASK1 vs FXR compounds in a NASH model at EASL in April, 2) Ph2a data for EDP-938 in an RSV challenge study mid-year, 3) Ph2s data for EDP-305 data in NASH in 3Q19, and 4) initiation of Ph1 study for EDP-514 in HBV in 2H19. Investors still focus on HCV royalties as the key driver of valuation for ENTA but the pipeline has become increasingly interesting. We update our model to reflect actuals and maintain our Perform rating and $100 PT.”
According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.2% and a 40.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Spero Therapeutics Inc.
Enanta Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $88.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $127.77 and a one-year low of $64.09. Currently, Enanta Pharmaceuticals has an average volume of 261.2K.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENTA in relation to earlier this year. Last month, Nathaniel Gardiner, the SVP & GC of ENTA bought 2,000 shares for a total of $69,400.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. Its brands include Mavyret and Viekira Pak.
